Efficacy and Safety of Concurrent Immune Checkpoint Inhibitors Combined with Radiotherapy or Chemoradiotherapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Single-arm Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Jun 12

PMID 38865375

Authors

Ran Cui

Yun Li

Xinlin Yu

Chun Wei

Ou Jiang

Affiliations

Soon will be listed here.

Abstract

Background: The recent usage of immunotherapy combined with chemoradiotherapy has improved survival in advanced non-small cell lung cancer (NSCLC) patients. However, determining the most effective therapy combination remains a topic of debate. Research suggests immune checkpoint inhibitors (ICIs) post-chemoradiotherapy enhance survival, but the impact of concurrent ICIs during chemoradiotherapy on rapid disease progression is unclear. This meta-analysis aims to assess the effectiveness and safety of concurrent ICIs with radiotherapy or chemoradiotherapy in advanced non-small cell lung cancer.

Methods: We searched PubMed, Embase, the Cochrane Library, and Web of Science for relevant studies, extracting data on overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs).

Results: The analysis included ten studies with 490 participants. Stage III NSCLC ORR was 81.8%, while Stage IV ORR was 39.9%. One-year PFS and OS for Stage III were 68.2% and 82.6%, compared to 27.9% and 72.2% for Stage IV. Common adverse events included anemia (46.6%), nausea (47.6%), rash (36.4%), and radiation pneumonitis (36.3%).

Conclusions: Our meta-analysis shows concurrent ICIs with chemoradiotherapy are effective and safe in advanced NSCLC, particularly in stage III patients at risk of progression before starting ICIs after chemoradiotherapy. The findings support further phase III trials. The review protocol was registered on PROSPERO (CRD42023493685) and is detailed on the NIHR HTA programme website.

Citing Articles

Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis.

Maimaitiyiming N, Li Y, Cao Y, Li Y Ther Adv Med Oncol. 2024; 16:17588359241284904.

PMID: 39376584 PMC: 11457245. DOI: 10.1177/17588359241284904.

References

Ettinger D, Wood D, Akerley W, Bazhenova L, Borghaei H, Camidge D . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016; 14(3):255-64. PMC: 10181272. DOI: 10.6004/jnccn.2016.0031. View

Preti B, Sanatani M, Breadner D, Lakkunarajah S, Scott C, Esmonde-White C . Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer. Curr Oncol. 2023; 30(8):7713-7721. PMC: 10453685. DOI: 10.3390/curroncol30080559. View

Guberina N, Wirsdorfer F, Stuschke M, Jendrossek V . Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis - The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging. Neoplasia. 2023; 39:100892. PMC: 10124136. DOI: 10.1016/j.neo.2023.100892. View

Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Alvarez R . Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology.... J Thorac Oncol. 2020; 16(2):278-288. DOI: 10.1016/j.jtho.2020.10.129. View

Davar D, Zarour H . Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors. Methods Mol Biol. 2019; 2055:23-60. PMC: 7382898. DOI: 10.1007/978-1-4939-9773-2_2. View

Denault M, Feng J, Kuang S, Shokoohi A, Leung B, Liu M . Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression. Curr Oncol. 2023; 30(8):7499-7507. PMC: 10453050. DOI: 10.3390/curroncol30080543. View

Xuan L, Bai C, Ju Z, Luo J, Guan H, Zhou P . Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy. Cytokine Growth Factor Rev. 2023; 75:1-11. DOI: 10.1016/j.cytogfr.2023.11.003. View

Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M . Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020; 8(2). PMC: 7555111. DOI: 10.1136/jitc-2020-001001. View

Chen Y, Gao M, Huang Z, Yu J, Meng X . SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol. 2020; 13(1):105. PMC: 7390199. DOI: 10.1186/s13045-020-00940-z. View

10.

Kashihara T, Nakayama Y, Okuma K, Takahashi A, Kaneda T, Katagiri M . Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol. 2023; 180:109454. DOI: 10.1016/j.radonc.2022.109454. View

11.

Brandmaier A, Formenti S . The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity. Semin Radiat Oncol. 2020; 30(2):139-144. DOI: 10.1016/j.semradonc.2019.12.005. View

12.

Mithoowani H, Febbraro M . Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. Curr Oncol. 2022; 29(3):1828-1839. PMC: 8946954. DOI: 10.3390/curroncol29030150. View

13.

Avrillon V, Daniel C, Boisselier P, Le Pechoux C, Chouaid C . Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program. Lung. 2022; 200(1):95-105. DOI: 10.1007/s00408-022-00511-8. View

14.

Conibear J . Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer. Br J Cancer. 2020; 123(Suppl 1):10-17. PMC: 7735212. DOI: 10.1038/s41416-020-01070-6. View

15.

Zayed S, Louie A, Breadner D, Palma D, Correa R . Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions. Ther Adv Med Oncol. 2023; 15:17588359231183668. PMC: 10331344. DOI: 10.1177/17588359231183668. View

16.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Tang S, Cong X, Zheng D, Chen C, Liu Z, Gao J . Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study. Front Oncol. 2023; 13:1129989. PMC: 10157220. DOI: 10.3389/fonc.2023.1129989. View

19.

Jabbour S, Berman A, Decker R, Lin Y, Feigenberg S, Gettinger S . Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol. 2020; 6(6):848-855. PMC: 7042914. DOI: 10.1001/jamaoncol.2019.6731. View

20.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View